advertisement
Abstract #18093 Published in IGR 9-2
Diurnal IOP control with bimatoprost versus latanoprost in exfoliative glaucoma: a crossover, observer-masked, three-centre study
Konstas AG; Holló G; Irkec M; Tsironi S; Durukan I; Goldenfeld M; Melamed SBritish Journal of Ophthalmology 2007; 91: 757-760
AIM: To evaluate the diurnal intraocular pressure (IOP) control and safety of bimatoprost versus latanoprost in exfoliative glaucoma (XFG). METHODS: One eye of 129 consecutive patients with XFG (mean (SD) age 66.5 (8.3) years) was included in this prospective, observer-masked, three-centre, crossover comparison. After a 4-6 week medicine-free period patients were randomised to bimatoprost or latanoprost monotherapy for 3 months. Patients were then switched to the opposite treatment for another 3 months. At the end of the washout and the treatment periods diurnal IOP was measured at 0800, 1300, and 1800. RESULTS: At baseline the IOP (mean SD) was 28.0 (4.0), 26.9 (3.6), and 25.9 (3.6) mmHg, at the three time points, respectively. Both treatments significantly reduced mean diurnal IOP at month 3. Mean diurnal IOP was 26.9 (3.5) mmHg at baseline, 17.6 (3.3) mmHg with bimatoprost, and 18.6 (3.6) mmHg with latanoprost (p< 0.0001). Furthermore, lower IOP values were obtained with bimatoprost at all time points (17.9 (3.4), 17.3 (3.3), and 17.6 (3.5) mmHg, respectively) compared with latanoprost (18.7 (3.6), 18.5 (3.6), and 18.6 (4.1) mmHg, respectively). The corresponding mean differences (0.8, 1.1, and 1.0 mmHg, respectively) were all significant (p< 0.001 for each comparison). Significantly more patients with XFG obtained a target diurnal IOP < 17 mmHg with bimatoprost than with latanoprost, 55/123 (45%) v 34/123 (28%); (p = 0.001), and significantly fewer patients were non-responders with bimatoprost than with latanoprost (5 v 13, p = 0.021). More patients reported at least one adverse event with bimatoprost than with latanoprost (58 v 41 at 3 months; p = 0.0003). CONCLUSION: This crossover study suggests that better diurnal IOP control is obtained with bimatoprost than with latanoprost in patients with XFG.
Dr. A.G. Konstas, Glaucoma Unit, 'A' University Department of Ophthalmology, AHEPA Hospital, 1 Kyriakidi Str, Thessaloniki 546 36, Greece. konstas@med.auth.gr
Classification:
9.4.4.1 Exfoliation syndrome (Part of: 9 Clinical forms of glaucomas > 9.4 Glaucomas associated with other ocular and systemic disorders > 9.4.4 Glaucomas associated with disorders of the lens)
11.4 Prostaglandins (Part of: 11 Medical treatment)
